No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 14 of the 40 quarters in the window, leaving 26 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.5x · 10Y median 3.4x · 5th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:43:47.872Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Xenetic Biosciences, Inc. (XBIO) stock was $2.12 as of Oct 6, 2026, 4:00 PM EDT, down 3.64% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -32.4% · 3-year avg -18.7%/yr · 5-year avg -34.5%/yr
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART.
Biotechnology · Framingham, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2020-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.22
vs Estimate
$-0.52
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1XBIO | $4.86M | $2.12 | -3.64% | -32.39% | -34.54% | -41.64% | N/A |
| 2LIMN | $4.97M | $3.70 | -7.27% | -95.32% | N/A | N/A | vs XBIO |
| 3BGMS | $4.72M | $0.86 | -1.46% | -81.68% | N/A | N/A | vs XBIO |
| 4IMNN | $4.71M | $1.12 | -9.68% | -76.74% | -63.83% | -55.17% | vs XBIO |
| 5CALC | $4.69M | $1.49 | -3.25% | -90.27% | N/A | N/A | vs XBIO |
| 6LNAI | $5.12M | $1.13 | -0.88% | -88.84% | N/A | N/A | vs XBIO |
forward FY estimate
N/A
$660601.00
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$2.12
High
N/A
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.32 | $-3.32 | $-3.32 | 1 |
| FY 2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $3.00M | $3.00M | $3.00M | 1 |
| FY 2027 | $2.50M | $2.50M | $2.50M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
